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Summary Type A prostaglandins (PGA, and 16,16-dimethyl-PGA2-methyl ester) were found to block the
proliferation of HTLV-I infected cord blood lymphocytes (CBL) in vitro, thus preventing the clonal immor-
talisation that is considered as a predisposing condition to HTLV-I positive leukaemia. PGA, and di-M-PGA2
did not affect the long-term survival of normal non-infected CBL, whereas they suppressed the proliferation of
an established cord-blood derived HTLV-I positive cell line, MT-2. As shown by the number of HTLV-1
infected pl9+ cells, the block of the selection of immortalised, infected clones by PGAs did not appear to be
due to an inhibition of early stages of HTLV-I infection. The possibility that the effect of PGAs could be
mediated by an action on the immune response was also examined. PGAs regulated the cell-mediated
cytotoxic function of CBL to a different extent when normal non-infected or HTLV-I exposed CBL were
compared. In fact, PGAs down-regulated the natural killing and macrophage/lymphocyte cytotoxic response
of normal CBL, whereas they did not modify the already depressed immune response of CBL challenged with
HTLV-I. These results suggest that the protective effect of PGAs against HTLV-I infection in vitro is mostly
related to the direct suppression of the clonal expansion of virus-infected cells, rather than to the anti-viral
activity or modulation of the cell-mediated immunity.
Human T-cell leukaemia/lymphoma virus type I (HTLV-I) is
an oncogenic retrovirus that was found to be involved in the
transformation of CD4+ lymphocytes into malignant leu-
kaemic cells both in vivo and in vitro (Wong-Staal & Gallo,
1985). Transformation can occur after integration of the
HTLV-I provirus in the host genome and requires a variable
latency period before the appearance of the leukaemic state.
Active virus replication does not seem to be required at this
stage to maintain the transformed phenotype (Franchini et
al., 1984), whereas it is relevant in the early phase of infec-
tion.
Although the worldwide distribution of HTLV-I positive
leukaemia is at present restricted to defined geographical
areas (Gallo, 1985; Manzari et al., 1985; Yoshida, 1987), the
possibility of counteracting pharmacologically the spreading
of infection in the future mainly relies on the understanding
of the mechanisms of infection and virus-induced transforma-
tion. Specific inhibitors of the HTLV-I replicative cycle are
very attractive, because they could be effective early, before
the clonal selection of HTLV-I transformed lymphocytes. On
the other hand, agents that can potentiate the host immuno-
surveillance against virus-infected cells might also help to
overcome first the spreading of virus particles and later the
survival of leukaemic cells.
Type A prostaglandins (PGAs) have been shown to possess
both anti-viral and anti-proliferative properties. Dose-depen-
dent anti-viral activity was demonstrated in the case of PGA,
and PGA2 in a number of viral infections both in vitro
(Santoro, 1987; Santoro et al., 1980) and in vivo (Santoro et
al., 1988). The highest effective concentration (4 .g ml-') was
not toxic to cultured cells and in the case of Sendai virus
(Santoro et al., 1981) it prevented the establishment of persis-
tent infection. The mechanism of the antiviral action is not
yet known, but in most models studied PGA treatment
induced alterations in the synthesis and/or maturation of
specific virus proteins (Santoro, 1987). In addition to their
anti-viral activity, PGAs can suppress the rate of tumour cell
proliferation and promote cell differentiation in a large num-
ber of systems (Olsson et al., 1982; Santoro, 1987; Santoro et
al., 1986; Santoro & Jaffe, 1989), in some cases by poten-
tiating the effect of other inducers, such as retinoic-acid
(Olsson et al., 1982). In human K562 erythroleukaemia, the
anti-proliferative activity of PGAs is associated with the
induction of a p74 cellular protein and the suppression of at
least two proteins, p92 and p46 (Santoro et al., 1986).
Moreover, prostaglandins (PGs) are known to be involved in
the regulation of the immune response in tumour-bearing
hosts (Bayley & Fletcher-Cientat, 1987; Bonta & Ben Efraim,
1987).
These combined effects of PGs were highly suggestive for
possible modulating effects of PGAs in HTLV-I infection
and transformation. In the present human model of virus-
induced leukaemogenesis, infection can be obtained in vitro
by co-culturing permissive target cells with a lethally irrad-
iated HTLV-1 donor tumour cell line, thus allowing study of
all the intermediate steps from infection to immortalisation.
Multiple treatments of these co-cultures with 4 tg ml-' PGA,
or the PGA2 analogue 16,16-dimethyl-PGA2-methyl ester did
not inhibit early stages of virus infection. However, at later
stages the selection of immortalised clones was impaired by
PGA treatment, as a consequence of the reduced prolifera-
tion rate of HTLV-I infected lymphocytes, which showed a
survival pattern comparable to that of non-infected controls.
Materials and methods
Cell cultures and infection
Human mononuclear cells (CBL) were isolated from hepar-
inised neonatal umbilical cord blood by Ficoll-hypaque gra-
dients (Pharmacia, Uppsala, Sweden) and cultured in 24-well
tissue culture plates or 25 cm2 flasks (Falcon, Oxnard, USA)
in RPMI 1640 culture medium (Gibco, Grand Island, USA)
supplemented with 20% heat-inactivated fetal calf serum
(Gibco), 2 mM glutamine (Gibco), 100 U ml-' penicillin/
streptomycin, and 20 U ml-' recombinant interleukin 2 (IL-
2, kindly provided by Hoffmann-La Roche, Basel, Switzer-
land). For macrophage cultures, supplemented McCoy's 5 A
medium (Gibco), enriched with bovine embryo extracts (Dif-
co, Detroit, USA) (D'Onofrio & Paradisi, 1983) and without
addition of IL-2, was used.
K562 human erythroleukaemia (Lozzio & Lozzio, 1975)
and the HTLV-I donor MT-2 cells, a cord blood CD4+
established human cell line (Miyoshi et al., 1981), were also
grown in supplemented RPMI 1640 culture medium, in the
absence of IL-2.
Freshly isolated CBL were infected in vitro by co-culture
with lethally irradiated MT-2 cells (12,000 Rad) at a CBL/
MT-2 ratio of 5:1 (Akagi et al., 1985). CBL/MT-2 co-cultures
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were routinely grown in supplemented RPMI 1640 medium,
containing 20 U ml-' IL-2. The culture medium was renewed
every week without splitting the co-culture until the concent-
ration of cells growing exponentially reached 106 cells ml-',
around 6 weeks post infection (p.i.). Fresh IL-2 was added
weekly at every change of medium. Infection was evaluated
by indirect immunofluorescence for the p19 viral core protein
(Robert-Guroff et al., 1981). An average of 600 cells was
scored for each duplicate sample and the percentages of
pl9+ cells in different samples were compared by x2 anal-
ysis.
Irradiation ofMT-2 cells in vitro
MT-2 (HTLV-I+) cells were irradiated in vitro with 12,000
Rad using a '37Cs irradiator (Gamma Cell 1000, model A,
AECL, Canada) delivering gamma rays at a rate of 1,000 rad
min-', suspended in culture medium in 50 ml tubes at a
concentration of 106 cells ml-'. The cells were then washed
twice, resuspended in the culture medium and kept at 4°C
until used.
Treatment with type A prostaglandins
PGA, (Sigma, St Louis, USA) and 16,16-dimethyl-PGA2-
methyl ester (di-M-PGA2) (kindly provided by J. Pike, Up-
john Company, Kalamazoo, USA) aliquots, dissolved in
ethanol at a concentration of 2 mg ml1 ', were stored at
-20°C and diluted in RPMI 1640 medium just before use.
As determined by radioimmunoassay, PGA is stable in tissue
culture medium, at 37°C, for about 24 h. Titration curves for
cell viability and virus infection were performed with increas-
ing concentrations of prostaglandins (from 0.5 to 8 jig ml-')
on CBL and tumour cell lines up to 3 weeks. A PGA
concentration of 4 pg ml-' was found to be capable of supp-
ressing the proliferation of infected CBL cultures 4-5 weeks
p.i. without affecting the survival of non-infected CBL cul-
tures. Therefore this concentration was used in all the experi-
ments described. PGAs were added every 4 days, starting
from the onset of the co-culture. In two separate experi-
ments, PGAs were added twice only in the first 48 h of the
CBL/MT-2 co-culture, to verify whether there could be some
4priming' effect on the immune response of CBL challenged
with HTLV-I donor allogeneic tumour cells.
Dot blot analysisfor viral DNA and RNA
Genomic DNA was extracted from CBL or MT-2 cells by
the standard proteinase K method. RNA extraction was
performed following the guanidine thiocyanate protocol
(Chirgwin et al., 1979). For dot blots, 3 jig DNA or RNA
samples were spotted on nitrocellulose filters (Schleicher &
Schiill, Dassel, FRG). DNA was denatured and neutralised
before spotting according to Kafatos et al. (1979). RNA
samples were dissolved in 1 volume H20 + 1 volume
20 x SSC solution + I volume formaldehyde, denatured by
heating at 65°C for 10 min and spotted on filters previously
equilibrated in 20 x SSC. All filters were air-dried and baked
for 2 h at 80°C.
Hybridisation was performed by using a 32P-nick-translated
probe corresponding to the SstI-SstI fragment of the HTLV-I
genome, isolated from the pMT-2 plasmid (kindly given by
R.C. Gallo). This 8.5 kb fragment accounts for almost the
entire HTLV-I genome. Nitrocellulose filters were hybridised
for about 20 h in 10 x Denhardt's solution, 4 x SET and
0.1% SDS as described by Graziani et al. (1987). Unspecific
background was removed by washing with decreasing salt
concentrations up to I x SET/0.r1% SDS. Kodak X AR 5
films (Kodak Company, Rochester, USA) were used for
autoradiography.
DNA and RNA synthesis in CBL/MT-2 co-cultures
3H-thymidine or 3H-uridine incorporation were tested in blast
cells during the first 4 weeks p.i. Cells (2 x 105 CBL per
well + 4 x I04 irradiated MT-2 cells per well) were plated on
day 0 in flat-bottomed 96-well microtitre tissue culture plates
(Falcon), methyl-3H-thymidine or 3H-uridine (Amersham In-
ternational, Amersham, UK) was added at the concentration
of 1 pCi per well and cells were harvested 18 h later by
microtitre cell harvester (Titertek 530, Flow Lab, Irvine,
UK). Samples were counted in a beta-scintillation counter
(LKB, Bromma, Sweden) and mean c.p.m.s of quadruplicate
groups were compared by t test analysis.
Indirect immunofluorescencefor thephenotype markers of
CBL/MT-2 co-cultures
Anti-Leu 2a (CD8), Leu 3a (CD4), Leu 4 (CD3), Leu M3
and IL-2 receptor (CD25) monoclonal antibodies were pur-
chased by Beckton and Dickinson (Milan, Italy) and used in
the indirect test for immunofluorescence under routine condi-
tions. FITC-conjugated anti-mouse F(ab')IgG were pur-
chased from Bio-Yeda (Rehovot, Israel) and anti-mouse IgM
(g) from KPL (Gaithesburg, USA). Air dried samples were
fixed for 20 min in ethanol/acetic acid (9:1) at - 20°C, rehyd-
rated by washing twice with cold PBS (phosphate buffered
saline pH 7.2) and stored at 4°C after being covered with
glycerol and cover slips. An average of 600 cells was scored
for each duplicate sample and the percentages of positive
cells were compared by x2 analysis.
Assayfor the cell-mediated cytotoxicity ofwhole CBL or
macrophages
The natural killer (NK) activity of CBL was tested on day 0
against the NK-susceptible K562 target cells at graded
effector/target cell ratios (E/T; 100:1, 50:1, 25:1 12.5:1) in a
4 h 5'Cr-release assay under routine conditions (Graziani et
al., 1987). CBL were pretreated overnight with 4jigml-'
PGA, or di-M-PGA2. The natural and antigen-specific cel-
lular cytotoxicity of PGA-treated CBL, co-cultured with MT-
2 cells, were respectively tested on day 7 p.i. against labelled
K562 or MT-2 target cells in a 4 h 51Cr-release assay. In two
separate experiments, cytotoxicity was evaluated on CBL
subpopulations isolated by a double adherence step. Non-
adherent cells (mostly lymphocytes, Ly) and adherent cells
(mostly monocytes, Mo) were separately treated with PGA
(4fig ml ') and tested on days 0 and 7 for cytotoxicity
against the NK-sensitive target K562 cells and the HTLV-I
donor MT-2 cells in a 4 h 5'Cr-release assay using 20:1, 10:1
and 5:1 E/T ratios. Alternatively, lymphocytes were infected
by co-culture with irradiated MT-2 cells under standard con-
ditions and added as inhibitory cells to autologous 7-day-old
macrophages (Mp) (1:1 ratio) pretreated (or not) with
4fig ml-' PGAI for 1 week, before testing for cell-mediated
cytotoxicity against K562 or MT-2 targets.
Per cent cytotoxicity was calculated according to the for-
mula:
% specific lysis=
c.p.m. sample release - c.p.m. autologous release
total c.p.m. x 100
and dose-response curves were obtained by plotting the
percentages of specific 5'Cr-release of different E/T ratios
(Thorn & Henney, 1976) and the number of killed cells (KC)
per million effector cells was calculated. Significance (P) was
calculated by regression test analysis.
Results
Effect ofPGA treatment on in vitro infection ofCBL with
HTLV-I
Non-stimulated human CBL can be kept in culture in the
presence of IL-2, in the condition described in the Methods
section, for 4-6 weeks. During the first week of culture,
DNA synthesis of CBL, measured by 3H-thymidine incor-
poration, was very low when the cells were cultured in thePGA PREVENTION OF HTLV-I + CLONES SELECTION 209
absence of IL-2. When 20 U ml-' IL-2 were added to the
medium, as routinely used for long-term lymphocyte cultures
(Akagi et al., 1985), isotope incorporation progressively in-
creased and peaked in the first week of culture (data not
shown). Graded amounts of PGAs (O.5-4ttg ml-') added to
IL-2 supplemented CBL cultures every 4 days until the
fourth week did not significantly decrease cell number and
viability. However, the marked increase of 3H-thymidine in-
corporation induced by the presence of IL-2 and herein
described was depressed by approximately 50% by PGA,
(4 igml-') addition (data not shown). This discrepancy be-
tween cell number and thymidine incorporation would reflect
a different balance between cell proliferation and death of
selected CBL subpopulations under the influence of IL-2
alone or IL-2 + PGA,. No early peak of 3H thymidine incor-
poration was detected when CBL were co-cultured with MT-
2 cells, in spite of IL-2 supply (data not shown).
When cord-blood derived (HTLV-I + ) MT-2 cells were
treated with PGAs, a dose-dependent inhibition of cell pro-
liferation was obtained. A single PGA treatment (4 jgml-')
was effective in inhibiting MT-2 proliferation (seeded at a
density of 10' cells ml-' in 24-well plates, 2 ml per well) for
72 h, without significantly altering cell viability (at 72 h cont-
rol 4.19 ± 0.08 x 105 cells ml-'; PGA, 1.65 ± 0.15 x 105 cells
ml-'; viability 96%). PGA, concentrations lower than
I jAg ml1' had no effect, whereas concentrations higher than
1OiLgml- completely prevented cell replication, but were
toxic to the cells (viability decreased to 89, 59 and 50% with
PGA, concentrations of 10, 15 and 30 ,.g ml-', respectively).
After co-culturing with MT-2 cells, CBL usually passed
through a growth crisis within the first 2-3 weeks of co-
culture. After this period, infected cells became predominant
and, approximately 12 weeks p.i., apparently immortalised
and occasionally independent of IL-2. Depending on different
donors, the proliferation rate of infected CBL in some
experiments increased already in the second week p.i., with-
out going through a growth crisis.
Addition of 4itg ml-' every 4 days of either PGA, or
di-M-PGA2 to CBL/MT-2 co-culture resulted in a remark-
able dose-dependent inhibition of the late CBL proliferation
and prevented the selection of immortalised HTLV-I +
clones (Table I and Figure 1). In six separate CBL/MT-2
co-cultures tested, PGA-treated CBL survived for 4 weeks in
the IL-2 enriched medium at levels comparable with normal
non-infected controls and within the sixth week practically all
cells died as expected for normal CBL (Table I). The kinetics
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Figure 1 Effect of PGA treatment on the growth (viable cells
ml-') of CBL/MT-2 cocultures (0-0). PGA, (4fig ml-',
O 0) or di-M-PGA2 (4gLgml-', A-A) were added to
the CBL/MT-2 cocultures following a multiple treatment scheme
(every 4 days, a) or a short-term treatment at the onset of the
coculture (day 0 and 2, b). 0-@, non-infected CBL cultures
(s.e. within 10% of the mean for quadruplicate samples).
of 'H-thymidine incorporation paralleled the patterns of cell
growth, showing no inhibition exerted by PGAs on the
minimal proliferation rate of CBL/MT-2 co-cultures within
the first week p.i. and a clear-cut inhibition of late CBL
proliferation, starting 2 weeks p.i. and resulting in a marked
suppression of 'H incorporation 4 weeks p.i. (Figure 2).
The effect of PGAs was strictly dependent on multiple
treatments. In fact, when PGAs were added only at the onset
of the co-culture (time 0) or in the first 2 days (time 0 and
Table I Time-course ofcell growth (viable cells ml-') ofCBL co-cultured with irradiated MT-2(HTLV-I
donor) cells after multiple treatments with PGA, or di-M-PGA2 (4tLgmlh' every 4 days)
Viable cells x 105 ml-'
I week 2 weeks 3 weeks 4 weeks 6 weeks
Experiment 1
CBL/MT-2 4.7 10.1 14.0 14.0 10.0
CBL/MT-2 + PGA, 3.8 3.0 1.0 0.5 0.0
CBL/MT-2 + di-M-PGA2 2.1 0.8 6.0 0.6 0.0
Experiment 2
CBL/MT-2 3.8 6.8 6.8 n.t. 9.3
CBL/MT-2 + PGA, 2.8 7.3 3.9 n.t. 0.0
CBL/MT-2 + di-M-PGA2 3.1 5.0 6.0 n.t. 0.0
Experiment 3
CBL/MT-2 2.8 1.2 1.3 3.6 7.2
CBL/MT-2 + PGA, 3.2 1.0 1.9 0.5 0.0
Experiment 4
CBL/MT-2 12.4 n.t. n.t. 1.5 n.t.
CBL/MT-2 + PGA, 5.3 n.t. n.t. 0.7 n.t.
Experiment 5
CBL/MT-2 3.4 4.2 6.4 5.5 9.8
CBL/MT-2 + PGA, 6.6 1.6 1.2 0.7 0.1
Experiment 6
CBL/MT-2 1.2 0.8 0.2 2.2 7.9
CBL/MT-2 + di-M-PGA2 1.2 0.4 0.0 0.0 0.0
n.t., not tested.210 C. D'ONOFRIO et al.
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Figure 2 Effect of multiple treatments with PGA1 (4 l.g ml-') on
the proliferation rate (3H-thymidine incorporation) of CBL/MT-2
co-cultures. 0 0, untreated CBL/MT-2 co-culture;
0 0, PGA, treated co-culture (s.e. within 10% of the mean
for quadruplicate samples). The viable cell numbers at 4 weeks
p.i. were 6 x 105 ml-' in the CBL/MT-2 culture and 0.7 x 105
ml-' in the PGA-treated co-culture.
48 h) of co-culture, late CBL proliferation was not impaired.
Moreover, in one experiment (shown in Figure 1) CBL pro-
liferation was even enhanced by a single PGA treatment and
the growth of HTLV-I infected cells appeared actually to be
favoured since PGA-treated CBL/MT-2 contained 35%
p19 + cells as compared to 10% present in untreated CBL/
MT-2 co-cultures at 8 weeks p.i.
Repeated PGA treatments either did not affect or in-
creased the percentage of p19 + CBL during the first 2 weeks
p.i. (Table II). At later stages of infection (i.e. 4 weeks p.i.)
the proportion of p19 + cells in PGA-treated co-cultures was
comparable to or lower than in untreated controls. In any
case, even in the co-cultures in which p19 expression was
increased at 2 weeks p.i., the anti-proliferative effect of re-
peated PGAs treatment on HTLV-I infected cells was
confirmed, since 'immortalised' HTLV-I + clones were
detected in controls but not in PGA-treated CBL/MT-2 co-
cultures.
HTLV-I integration and expression in CBL/MT-2 co-cultures
after PGA-treatment
The results obtained by dot blot analysis on genomic DNA
extracted from co-cultured CBL showed comparable
amounts of integrated provirus in PGA-treated and un-
treated CBL, 2 weeks p.i. (Figure 3). Four weeks p.i., no
integrated viral DNA was detectable in most PGA-treated
CBL/MT-2 cell preparations (data not shown). When virus
expression was tested, it was found that the amount of viral
RNA was greatly augmented in infected CBL after PGA-
treatment, 2 weeks p.i., approaching the amount detected in
the 100% p19 + MT-2 cells. No difference in the percentage
of p19 + cells was instead found between PGA-treated and
untreated CBL in the same experiment (Figure 3). However,
to this enhancement of HTLV-I mRNA in treated CBL there
was no corresponding increase of total RNA synthesis, since
no significant difference in 3H-uridine incorporation was
found when control CBL, CBLMT-2 co-cultures or CBL/
MT-2 PGA-treated co-cultures were compared, up to the
third week of co-culture (data not shown).
Expression ofphenotype markers in PGA-treated CBL/MT2
co-cultures
Data are summarised in Table II. A clear-cut picture can be
observed when non-infected CBL cultures are compared to
CBL/MT-2 co-cultures. Four days p.i., a general suppression
of phenotypic markers was noted in CBL/MT-2 co-cultures,
with the exception of a 3-4-fold increase of M3 phenotype,
which identifies monocyte/macrophage subsets. PGAs in-
creased the relative percentage of CD3 + and M3 + cells in
non-infected CBL cultures. No variation of CD3 marker was
observed in infected CBL following PGA treatment, whereas
M3 phenotype was significantly reduced. It follows that
PGAs would differently regulate monocyte proliferation in
CBL cultures when these are non-infected, as compared to
cultures exposed to HTLV-I infection.
No significant variation in the expression of IL-2 receptor
was found at early stages of HTLV-I infection and PGAs did
not further affect it (Table III). As expected, however, the
immortalised clones that arised from untreated CBL/MT-2
co-cultures, tested 12 weeks p.i., expressed high IL-2 receptor
and CD4 phenotype (data not shown).
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Figure 3 Dot blot analysis of genomic DNA or mRNA samples
(3 yg per spot) showing integration of HTLV-I provirus and its
expression in CBL/MT-2 co-cultures 15 days p.i., in the presence
or the absence of PGAI (4 jIg ml-'). Per cent p19 + cells are
reported in the third lane. CBL are negative control samples and
MT-2 cells are 100% positive for p19 protein.
Table 11 Time-course of p19 positivity in CBL co-cultured with irradiated MT-2 (HTLV-I donor) cells after
multiple treatments with PGAI (4glg ml-' every 4 days)
I week 2 weeks 4 weeks
Cells %pJ9 + p %pJ9 + p %pJ9 + p
Experiment I
CBL/MT-2 6.35 13.07 - 7.01
CBL/MT-2 + PGA, 7.92 n.s. 27.51 <0.01 8.48 n.s.
Experiment 2
CBL/MT-2 4.32 6.18 - 29.8 -
CBL/MT-2 + PGA, 6.47 n.s. 5.64 n.s. 10.7 <0.01
Experiment 3
CBL/MT-2 14.32 8.1 2.95 -
CBL/MT-2 + PGA, 13.42 n.s. 8.3 n.s. 4.77 n.s.
P, probability, calculated by x2 analysis.PGA PREVENTION OF HTLV-I+ CLONES SELECTION 211
Table III Variationin theexpression ofphenotypicmarkersinCBL/MT-2co-cultures ascompared to non-infected CBLand its
modulation by PGAs
IL-2 receptor
Leu 2a(CD8) Leu 3a(CD4) Leu 4(CD3) (CD25) Leu M3(CD14)
Sample Drug % P % P % P % P % P
CBL 30.86 - 27.25 - 48.90 - 9.45 - 6.12 -
CBL PGA, 29.34 n.s. 28.51 n.s. 51.79 n.s. 8.53 n.s. 12.13 <0.01
CBL di-M-PGA2 29.52 n.s. 33.74 <0.05 62.54 <0.01 8.03 n.s. 10.55 <0.01 CBL/MT-2 - 5.85 - 3.45 - 1.54 - 11.58 - 22.77 -
CBL/MT-2 PGA, 7.14 n.s. 3.18 n.s. 1.07 n.s. 14.72 n.s. 16.41 <0.01
CBL/MT-2 di-M-PGA2 8.31 n.s. 3.48 n.s. 1.25 n.s. 13.12 n.s. 13.24 <0.01
PGAs(4fLg ml ') wereadded onday0and 3, cells were thenharvested onday4and tested with themonoclonal antibody panel.
Expression of CD8, CD4 and CD3 markers was significantly decreased after co-culture of CBL with MT-2 cells (P<0.01),
whereas the percentage of cells expressing IL-2 receptor slightly increased and M3 subpopulation was significantly expanded (P<0.01). P was calculated by x2 analysis.
Cell-mediated immunity in PGA-treated CBL/MT-2
co-cultures
PGs are well known for their modulating activity on the
immune response. Therefore studies of cell-mediated im-
munity were performed in terms of: (a) cell-mediated natural
cytotoxicity against NK-susceptible K562 or relatively NK-
insensitive MT-2 target cells; (b) cytotoxic T lymphocyte
(CTL) response against MT-2 'sensitiser' cells; (c) macro-
phage-mediated cytotoxicity.
Freshly isolated CBL were incubated overnight at 37°C
with medium alone, or with medium containing 4jig ml-' of
PGA, or di-M-PGA2, washed and tested for NK activity
against K562 or MT-2 target cells. The results illustrated in
Figure 4 show that the cytotoxicity of effector cells against
K562 targets was significantly reduced by PGAs. The cyto-
lytic activity of CBL was marginal against MT-2 cells and
PGAs did not show any detectable effect.
CBL co-cultured with irradiated MT-2 cells in IL-2 en-
riched medium were tested for cytotoxicity against K562 and
MT-2 targets on day 7 p.i. The results show that: (a) the
cytolytic activity of CBL/MT-2 effectors against K562 or
MT-2 cells was respectively 40% or 87% lower than non-
infected controls (Figure 5, legend); (b) PGAs further in-
hibited the killing capacity of infected CBL against K562
targets, but slightly enhanced their cytotoxic activity against
MT-2 target cells (Figure 5).
Cord blood monocytes showed marginal cytotoxic activity
against both K562 and MT-2 target cells when tested on day
0 in a 4 h 5'Cr-release assay (Figure 6). After I week of
culture, monocytes differentiated into macrophages (Mp) and
acquired most functions of mature resident Mgp (D'Onofrio
& Lohmann-Matthes, 1984; D'Onofrio & Paradisi, 1983).
Targetcell:'K562- Targetcell: MT-2-
4.
co
0} Contro:l -U PGA1 Gl di-M-PGA2
Figure 4 Natural killing (NK) activity of freshly isolated CBL
against the NK-susceptible target K562 cells and its negative-
modulation by PGAs (P<0.01, calculated by regression analy-
sis). On the right side, the modest baseline killing capacity of
fresh CBL against MT-2 cells (expressing class I and II antigens)
is shown not to be affected by PGA treatment.
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Figure 5 Effect of PGA treatment on the cell-mediated cytotox-
icity of CBL/MT-2 co-cultured effector cells, tested on day 7 p.i.
against the NK-susceptible target K562 cells and against MT-2
cells. PGAs significantly reduced the 'anomalous killing' of CBL
against K562 target (P<0.01, calculated by regression analysis),
whereas they did not affect the killing of infected CBL against
MT-2 targets. Infection with HTLV-I (CBL/MT-2 co-cultures,
grown in medium supplemented with 20 U ml-' IL-2, tested 7
days p.i.), resulted in a clear-cut depression of CBL killing ability
(number of killed K562 target cells by CBL = 4,022, versus 2,396
killed cells by CBL MT-2 co-cultures, P<0.01; number of killed
MT-2 target cells by CBL = 1,840, versus 228 killed cells by
CBL/MT-2 effectors, P<0.01).
Their cytotoxic capacity against both K562 and MT-2 targets
increased markedly and was not affected by PGA treatment
(Figure 6). Autologous non-adherent mononuclear cells
(mostly T lymphocytes), cultured in IL-2 enriched medium
for 1 week, showed higher killing activity against both targets
as compared to Mp (see Figure 6, legend). In this case PGA
treatment of isolated lymphocytes profoundly inhibited their
killing activity against K562 targets (data not shown). When
7-day cultured non-adherent cells (i.e. Ly, see Figure 6)
where admixed with separately cultured Mg at 1:1 ratio and
used as effector cells in the cytotoxicity assay against both
K562 or MT-2 targets, the results (Figure 6) showed that: (a)
additive cytotoxic effects of Mgp + Ly were detected against
K562 cells, whereas antagonistic effects were found when
MT-2 targets were used; in this case the cytolytic effects were
less than the sum of Ly and Mg cytotoxicity, and did not
exceed that of Ly alone; (b) the killer activity of Mgp + Ly
against K562 or MT-2 cells was significantly inhibited by
PGA, treatment of Mgp on day 0, 3 and 6; (c) when Ly
exposed to HTLV-I infection (i.e. Ly/MT-2) were admixed
with Mgp, antagonistic effects on the cytolytic activity against
both K562 and MT-2 cells were detected; this was demon-
strated by the finding that in no case did the cytotoxicity of
Mp + Ly/MT-2 exceed that of Mp alone, in spite of a sub-
stantial lytic activity of Ly/MT-2 against K562 or MT-2 cells
as well (see Figure 6, legend); (d) pretreatment of Mp with212 C. D'ONOFRIO et al.
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Figure 6 Effect of PGA treatment on monocyte (day 0) and
macrophage (Mgp, day 7) cytotoxicity against NK-susceptible
K562 targets and against MT-2 (HTLV-I + ) cells. Mgp were
treated with 4 jg ml1' PGA, (hatched bars) on days 0, 3 and 6
tested for cytotoxicity on day 7 in a short-time 5'Cr-release assay
(4 h, as for lymphocyte test). Autologous lymphocytes (Ly) were
added to Mq cultures at 1:1 ratio just at the time of the test, and
the resulting killing capacity was compared by testing non-in-
fected or HTLV-I infected Ly (i.e. 7-day-old autologous Ly/MT-2
co-cultures grown in medium supplemented with 20 U ml-' IL-2).
The numbers of killed target cells in different conditions are also
reported. n killed K562 cells by: whole CBL = 4,022;
Ly = 20,128; Mg = 6,824; Ly + Mgp = 29,760 (in Figure). n killed
MT-2 cells by: whole CBL = 1,840; Ly = 16,504; Mp= 7,368;
Ly + Mgp = 16,336 (in Figure). n killed K562 targets by: whole
CBL/MT-2 co-cultures = 2,396; Ly/MT-2 = 5,704; (Ly/MT-
2)+ Mgp= 10,000 (in Figure). n killed MT-2 targets by: whole
CBL/MT-2 co-cultures = 228; Ly/MT-2 = 6,552; (Ly/MT-
2) + Mp = 7,200 (in Figure).
PGAs did not modify the cytotoxic activity of these cells
admixed with Ly exposed to HTLV-I infection, tested against
K562 or MT-2 targets.
Discussion
Infection with HTLV-I, as for other leukaemia viruses, is
usually followed by initial target cell proliferation, growth
crisis and virus-induced polyclonal hyperplasia of infected
cells that might undergo monoclonal selection and be immor-
talised in vitro (Hahn et al., 1984) or associate with ATL
leukaemia in vivo after a variably long latency period (Hahn
et al., 1984; Yoshida, 1987). This early virus-induced pro-
liferation of sensitive target cells can be considered a predis-
posing condition to stable transformation (Duesberg, 1987),
according with a multistep model of tumorigenesis and under
the control of specific host genes (Knudson, 1985). Hence, a
predictable tumour risk would depend on high virus expres-
sion and virus-induced hyperplasia. Prevention of this risk is
reasonably focused on the possibility of affecting these two
steps of retrovirus pathogenicity.
Interferon-P was recently shown to inhibit HTLV-I trans-
mission and integration in specific target cells, resulting in a
sharp decrease in the number of p19 + lymphocytes during
early weeks p.i. (D'Onofrio et al., 1988). However, early
interferon treatment of lymphocytes delayed the HTLV-I
induced hyperplasia, but did not prevent it. In contrast, when
type A prostaglandins were tested, no clear-cut inhibition of
HTLV-I infection was found 2-3 weeks p.i., but later the
virus-induced proliferation of lymphocytes appeared to be
greatly impaired by multiple PGA treatments, so that no
selection of HTLV-I infected clones apparently occurred.
Both PGA, and di-M-PGA2 were highly effective in preven-
ting the HTLV-I-induced hyperplasia when used at the con-
centration of4pg ml-'. PGAs also inhibited the proliferation
of the HTLV-I + MT-2 cells, an established T-cell line
derived from infected CBL (Miyoshi et al., 1981). On the
contrary, after a single treatment the prevalent effect of
PGAs on CBL/MT-2 co-cultures was an enhancement of
infection and the late proliferative phase was not impaired.
Multiple mechanisms of action ofprostaglandins may con-
tribute to the final results described here. A possible effect on
the replicative cycle of HTLV-I was first hypothesised, be-
cause of the potent anti-viral activity of PGAs demonstrated
in several DNA and RNA virus models and associated with
inhibition of specific virus protein synthesis (usually 'late'
proteins or glycoproteins) and block of virus maturation
(Santoro, 1987; Santoro et al., 1987). However, there is no
evidence that PGAs could inhibit replication of oncogenic
viruses. On the contrary, several prostaglandins (PGA,, PGB2
PGE2 and PGF2z) have been reported to enhance replication
of murine mammary adenocarcinoma virus (Karmali et al.,
1982; Svec et al., 1982) and of HIV (by PGE2; Ueno et al.,
1987). In our system, PGAs were found not to decrease and
in some cases even to enhance the degree of CBL infection
during the first 2 weeks p.i., as determined by the percentage
of pl9 + cells and by the amount of cytoplasmic viral
mRNA. Studies are in progress to define whether PGAs
affected transcription from integrated provirus or stabilisa-
tion of viral RNA. Moreover, a possible action of PGAs on
the synthesis and maturation of HTLV-I proteins has also to
be verified.
The ability ofmultiple PGA-treatments to prevent HTLV-I
induced hyperplasia and the selection of leukaemic clones
could be due to a direct anti-proliferative effect of PGAs. In
fact, they have been shown to inhibit cell proliferation and/or
promote differentiation in several leukaemic mouse and
human cell lines; this activity was found to be dependent on
the stage of cell differentiation and on the phase of the cell
cycle, and usually was not related to cAMP metabolism
(Santoro, 1987; Santoro et al., 1986; Santoro & Jaffe, 1989).
In particular, the antiproliferative effect of PGAs was dose-
dependent, reversible depending on the length of treatment
and associated with inhibition of protein synthesis and gly-
cosylation (Santoro, 1987; Santoro et al., 1986).
HTLV-I infection is followed in vitro and in vivo by re-
markable alteration of the immune response (De Vecchis et
al., 1985; D'Onofrio et al., 1988; Sociu-Foca et at., 1984;
Volkman et al., 1985; Yarchoan et al., 1986) and it has been
suggested that the indiscriminant helper function of infected
T lymphocytes plays a major role in the auto-maintenance of
the leukaemic state (Volkman et al., 1985). These observa-
tions suggested the possibility that the effect of PGAs des-
cribed could be mediated by interaction with the host's
immune system challenged by exposure to the virus. The in
vitro and possibly in vivo pattern of the first step of HTLV-I
infection implies a cell-to-cell virus transmission accompanied
by donor-recipient allogeneic interaction, which elicits a T-
cell mediated immune response that in turn could restrain
HTLV-I infection. Following this initial step, elimination of
autologous virus infected cells is strictly dependent on the
efficiency of killing by effector monocytic and lymphocytic
cells.
The effects of PGAs on the whole CBL population or on
Ly and Mgp effector cells were analysed separately to ascer-
tain whether PGAs could be involved in ultimate virus supp-
ression mediated by the killing of virus-infected cells.
Actually PGA treatment did not increase the spontaneous
cytotoxicity of cultured Mgp or Mgp+ Ly, or the CTL-med-
iated cytolysis of supposedly allosensitised effector cells (i.e.
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Mp+ (Ly/MT-2), against MT-2 targets. This finding does
not support the hypothesis that immune mechanisms would
play a key role in the PGA-induced suppression of the
outgrowth of HTLV-I infected clones, potentially capable of
inducing CTL responses (Mitsuya et al., 1983). The transient
but remarkable depression of the majority of lymphocyte
markers except for M3 antigens in CBL exposed to virus
infection is difficult to interpret. However, this occurrence
might contribute to an explanation of the failure of potential
immunosurveillance mechanisms to control the emergence of
the infected clone. The influence of PGA treatment on these
parameters was modest, except for M3. In this case PGAs
increased or decreased the percentage of M3 positive cells in
cultured control CBL or CBL/MT-2 respectively. Studies are
in progress to elucidate the role of Mp in the early phase of
infection.
In conclusion, the present data suggest that PGAs could
play a significant role in controlling HTLV-I infection by
non-immunological mechanisms. Further studies are in pro-
gress to explore whether PGA treatment combined with
immunomodulating agents (i.e. agents capable of antagonis-
ing the immune depression that follows the infection with
HTLV-I) would improve the efficiency of in vitro control of
infection, in the attempt to elaborate experimental protocols
for prevention of HTLV-I related disease in seropositive
subjects.
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